Patent SG-11201909214Y-A (SG)
Title: System and process for treatment of myopia
Inventor: LUTTRULL JEFFREY K
IPC: A61B18/04
Filed: 2017-12-05
Abstract: Title: SYSTEM AND PROCESS FOR TREATMENT OF MYOPIA 30 32 34 FIG. 3 ................. ........ .......... 38 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) iii111111110111010100111110l0 01010111100111111101110 011 (10) International Publication Number WO 2018/203930 Al WIPO I PCT (51) International Patent Classification: A61B 17/00 (2006.01) A61B 18/12 (2006.01) A61B 18/00 (2006.01) A61B 18/18 (2006.01) A61B 18/04 (2006.01) A61B 18/20 (2006.01) (21) International Application Number: PCT/US2017/064708 (22) International Filing Date: 05 December 2017 (05.12.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15/583,096 01 May 2017 (01.05.2017) US 15/629,002 21 June 2017 (21.06.2017) US (71) Applicant: OJAI RETINAL TECHNOLOGY, LLC [US/US]; 283 Came Road, Ojai, California 93023 (US). (72) Inventors: LUTTRULL, Jeffrey K.; 283 Came Road, Ojai, California 93023 (US). CHANG, David B.; 14212 Livingston, Tustin, California 92780 (US). MARGOLIS, Benjamin W. L.; 2879 MacArthur Blvd, Oakland, Califor- nia 94602 (US). (74) Agent: KELLEY, Scott W.; Kelly & Kelley, LLP, 6320 Canoga Avenue, Suite 1650, Woodland Hills, California 91367 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, cr O 00 O C (57) : A process for preventing or treating myopia includes applying a pulsed energy, such as a pulsed laser beam, to tissue of an eye having myopia or a risk of having myopia. The source of pulsed energy has energy parameters including wavelength or frequency, duty cycle and pulse train duration, which are selected so as to raise an eye tissue temperature up to eleven degrees Celsius to achieve therapeutic or prophylactic effect, such as stimulating heat shock protein activation in the eye tissue. The average temperature rise of the eye tissue over several minutes is maintained at or below a predetermined level so as not to permanently damage the eye tissue. [Continued on next page] WO 2018/203930 Al MIDEDIMOMOIDEIRDERI001010111001fiMODEVOIS TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))